NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR

NextCure announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate ADC developed in partnership with LigaChem Biosciences LCB , formerly LegoChem Biosciences, , at the 2024 American Association for Cancer Research AACR Annual Meeting in San Diego, CA. The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity. LNCB74 is an ADC utilizing LigaChem Biosciences’ proprietary site-specific conjugation and plasma-stable, cancer selectively activating linker technology to link monomethyl auristatin E MMAE to a B7-H4 targeting antibody in a drug-to-antibody ratio of 4 DAR4 . The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers. “LNCB74 was developed through NextCure’s expertise in B7-H4 tumor biology and LCB’s ConjuAllTM technology, resulting in a potent ADC with initial data demonstrating excellent tolerability and pharmacokinetics,” said Solomon Langermann, Ph.D., NextCure’s chief scientific officer. “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications. We look forward to continuing our work building a robust preclinical dataset to further support advancing this ADC to the clinic.”…LNCB74 was engineered for an improved safety profile and therapeutic index with increased stability in circulation, tumor selective payload release, and a reduction in off-target release of active payload, mitigating toxicity compared to traditional vedotin ADCs.